PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and NRF2 Activation
Diallo, K.; Degboé, Y.; Baron, M.; Bellin-Robert, A.; Boyer, J.F.; Constantin, A.; Ruyssen-Witrand, A.; Rauwel, B.; Cantagrel, A.; DAVIGNON, J. Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and NRF2 Activation. Preprints2024, 2024021740. https://doi.org/10.20944/preprints202402.1740.v1
APA Style
Diallo, K., Degboé, Y., Baron, M., Bellin-Robert, A., Boyer, J.F., Constantin, A., Ruyssen-Witrand, A., Rauwel, B., Cantagrel, A., & DAVIGNON, J. (2024). Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and NRF2 Activation. Preprints. https://doi.org/10.20944/preprints202402.1740.v1
Chicago/Turabian Style
Diallo, K., Alain Cantagrel and Jean-Luc DAVIGNON. 2024 "Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and NRF2 Activation" Preprints. https://doi.org/10.20944/preprints202402.1740.v1
Abstract
(1) Background: TNF inhibitors (TNFi) have revolutionized the treatment of rheumatoid arthritis (RA). However, 30-40 % of RA patients do not respond adequately to those biologics. In addition to neutralizing soluble TNF, TNFi have the ability to bind the transmembrane form of TNF, tmTNF. Importantly, tmTNF can act itself as a receptor that induces a “Reverse Signaling” (RS) in cells. We previously showed that certolizumab, a Fab’ TNFi, activates RS in human primary monocytes, at least in part through the transcription factor NRF2 that is known to regulate the expression of genes involved in anti-inflammatory response and oxidative stress. (2) Methods: Here, we have developed an assay for the prediction of clinical response of RA patients to TNF inhibitors. This assay is based on mRNA quantitation of CD36 activation and of 6 genes induced by NRF2 following tmTNF RS in fresh monocytes. (3) Results: We could predict the response to anti-TNF monoclonal antibodies (mAbs) with 93.3 % accuracy. However, our method was not suitable for the prediction of the response to TNF soluble receptor etanercept. (4) Conclusions: We have developed a rather simple, short-term, test that can be standardized. Predicting the response to TNF mAbs will help physicians offer the best available treatment and provide patients with personalized medicine.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
